Reliable detection of neurological biomarkers in blood and cerebrospinal fluid (CSF) remains a key challenge in neurodegenerative disease research. Many of these markers are present at very low concentrations, and biological samples can contain components that interfere with accurate measurement.
The Tecan-IBL Neuro IP product portfolio supplied by Roboscreen, is available in the UK and Ireland through Oxford Biosystems and is designed to address these challenges through pre-analytical immunoprecipitation and enrichment of low-abundance neurological biomarkers from cell-free body fluids prior to downstream analysis.
Improved detection through targeted enrichment
The Neuro IP Kit is recommended for use alongside IBL-Tecan’s magnetic Immuno Beads, available for a range of neurological targets. These beads are coated with monoclonal antibodies directed against proteins including various forms of human tau, beta-amyloid, and alpha-synuclein, enabling selective enrichment prior to downstream analysis. Additional targets may also be available on request.
This antibody-based capture system selectively binds target proteins from cell-free biological fluids, including plasma, serum, and CSF
|
Figure1. Improved diagnostic performance of the Lumipulse® G pTau181 assay following Tau-IP enrichment
|
Figure 2. Enhanced separation of Alzheimer’s disease and control samples using SIMOA™ analysis of Tau-IP eluates compared with direct plasma measurement.
|
As shown in Figures 1 and 2 above, the Neuro IP kit enables enrichment of target proteins and reduces background interference, enhancing the sensitivity and reliability of downstream detection. This can support clearer and more consistent measurements across a range of analytical platforms, including the MESO QuickPlex, ELECSYS®, SIMOA™, LUMIPULSE®, and ELISA-based methods.
Complementary neurodegeneration assays from IBL-Tecan
To support broader neurodegeneration research, IBL-Tecan also offers a range of assays for the measurement of key neurological biomarkers in blood and CSF.
These include:
- Total tau and phosphorylated tau isoforms (Alzheimer’s disease research), including a new luminescence immunoassay for Brain-Derived Tau (BD-Tau) in plasma samples
- Amyloid beta peptides (Aβ40 and Aβ42, associated with amyloid plaque pathology in Alzheimer’s disease)
- Alpha-synuclein (linked to Parkinson’s disease and related disorders)
- Neurofilament light chain (NfL, a marker of neuronal damage) – kits are available for use with serum and CSF samples
Used alongside the Neuro IP Kit, these assays enable a combined enrichment and detection workflow that can improve data quality, sensitivity, and consistency in neurodegenerative disease research.
If you are interested in exploring IBL-Tecan's wider neurodegeneration portfolio, you can download the Neurodegeneration Brochure for an overview of available assays, biomarkers, and research applications.
For additional background information on neurodegenerative disease biomarkers and current research approaches, visit IBL-Tecan's Neurodegenerative Diseases Article, which also includes further reading and references.
Further information
If you would like further information on the Neuro IP Kit, discuss suitability for specific research applications, or review our wider neurodegeneration portfolio from IBL Tecan and other suppliers, please contact us.
Get in touch to discover more
Elecsys® is a trademark of Roche Diagnostics GmbH.
SIMOA® is a trademark of Quanterix Corporation.
Lumipulse® is a trademark of Fujirebio Inc.